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Figure 1: Chalcone synthesis reaction scheme (1a-1o)
Figure 2: Scanning electron micrographs of untreated and 10 X MIC (60 µg/ml) 1a treated 
Mycobacterium bovis BCG cells for 5 days. (a-c) untreated M. bovis BCG cells; (d-f) 60 µg/ml 
1a treated M. bovis BCG cells analyzed using JEOL CarryScope JCM-5700 scanning electron 
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d e f
microscope. There was significant proportion (76%) of cells showing morphological changes 
such as bulging, elongation and wrinkling of cell surface.
Figure 4: Investigation of the impact of InhA overexpression on sensitivity to compound 1a.  
Absorbance values were read at 0 days and after 7 days for EV and InhA strain.  Using 
Mycobacterium bovis BCG containing a constitutive plasmid (pMV261) expressing InhA, IC50 
was compared to an empty vector control.  The overexpressing strain demonstrated an 
increase in IC50 value 16 g.ml-1 compared to 8 g.ml-1 for the empty vector strain. The 
experiments were performed in biological replicates of n=3 and the error bars represent the 
standard error bars of mean (SEM).
Figure 5: Saturation binding assay using intrinsic tryptophan fluorescence to quantify 
association of increasing concentrations of ligands 1a and triclosan with InhA (n=3). The 
figure shows the Kd values (11.65 µM and 10.29 µM) for triclosan and 1a. Data were fitted 
using GraphPad Prism, relative fluorescence units (RFU). The experiments were performed 
in biological replicates of n=3 and the error bars represent the standard error bars of mean 
(SEM).
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Figure 6: 6a shows the predicted interaction mode of compound 1a within the binding site 
of the InhA of Mycobacterium tuberculosis. InhA is shown as secondary structures with 
helices (green) and sheets (yellow). Compound 1a is shown in the teal capped stick format. 
Van der Waals surface around compound 1a is shown in mesh format. NAD is shown in 
element type format (Nitrogen in blue, Oxygen in red, Phosphorous in magenta). Pi-Pi 
stacking interaction is shown as teal dashed line between the phenyl rings of Phe 149 and 
the compound 1a. This image has been generated by using Schrodinger drug design 
software. 6b shows the ligand interaction map of the compound 1a with the active site 
residues of the InhA. The proposed interaction mode of compound 1a is shown in the stick 
format. Pi-Pi stacking is shown in green line. 
Highlights:
· Chalcone 1a inhibits the growth of Mycobacterium bovis BCG (MIC 6ug/ml), a model organism 
for Mycobacterium tuberculosis
· Chalcone 1a directly targets inhA 
· Inhibition by Chalcone 1a results in reduction of cell wall mycolates 
Table 1: Shows chalcone compounds 1a to 1o with various substituents at R1, R2 and R3 positions 
with their molecular weights and predicted Clogp values.  The MIC of each compound is shown in 
µg.ml-1 against M.bovis BCG with the IC50 values and the selective index (SI) for J774 cell line. 
Lipophilicities calculated by ChemDraw Professional 15.0, part of ChemOffice (Perkin Elmer, UK).
Compound         Substituents            MIC 
(µg.ml-1)                                                         
J-774 
(IC50)
(µg.ml-1)                                                         
SI= 
IC50/MIC
R1 R2 R3
Mol.wt
(g.mol-1)
Clogp
M.bovis 
BCG
1a H H H 270.33 3.35 6.25 50 8.0
1b H Br H 349.22 4.18 - 25 -
1c Br H H 349.22 4.18 25 25 1
1d H H Br 349.22 4.18 12.5 25 2.0
1e H Cl H 304.77 3.91 - 12.5 -
1f Cl H H 304.77 3.91 12.5 12.5 1
1g H H Cl 304.77 3.91 200 12.5 0.06
1h H H F 288.32 3.51 25 100 4
1i H H OCH3 300.35 3.23 50 100 2
1j H H CH3 284.35 3.84 25 25 1
1k H H C6H5 346.43 5.03 100 25 0.25
1l H NO2 H 315.32 3.48 100 25 0.25
1m CH3 H H 284.35 3.84 50 25 0.5
1n H H NO2 315.32 3.48 200 50 0.25
1o Cl H Cl 339.21 4.47 200 6.25 0.03
RIF - - - 0.1
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Identification and validation of the mode of action of the chalcone anti-mycobacterial compounds
Highlights:
· Chalcone 1a inhibits the growth of Mycobacterium bovis BCG (MIC 6.25 µg.ml-1), a model organism 
for Mycobacterium tuberculosis
· Chalcone 1a directly targets InhA 
· Inhibition by Chalcone 1a results in reduction of cell wall mycolates 
Abstract
Objectives:  The search for new TB drugs has become one of the great challenges for modern 
medicinal chemistry. An improvement in the outcomes of TB chemotherapy can be achieved by the 
development of new, shorter, cheap, safe and effective anti-TB regimens. 
Methods: Chalcones (1a-1o) were synthesized and evaluated for their antimycobacterial activity 
against Mycobacterium bovis BCG using growth inhibition assays.  Compound 1a was selected as a 
‘hit’ compound. The mode of action of compound 1a, was identified by mycolic acid methyl esters 
(MAMEs) and fatty acid methyl esters (FAMEs) analysis using thin layer chromatography. Dose 
dependent experiments were conducted by over-expressing components of FAS-II in M. bovis BCG to 
confirm the target. Ligand binding using intrinsic tryptophan assay and molecular docking were used 
to further validate the target. 
Results: MAMEs and FAMEs analysis showed dose-dependent reduction of MAMEs with the overall 
abundance of FAMEs suggesting that compound 1a targets mycolic acid biosynthesis. Direct binding 
of 1a to InhA was observed using an intrinsic tryptophan fluorescence binding assay, and a 2-fold IC50 
shift was observed with an InhA overexpressing strain confirming InhA as the cellular target.  
Conclusion: The chalcone 1a exhibits potent antimycobacterial activity, displays a good safety profile 
and is a direct inhibitor of InhA, a key component in mycolic acid synthesis, validating this series for 
further anti-TB drug development.
Key Words: Chalcones, Tuberculosis, MIC, InhA, Mycolic Acids, Docking
1 Introduction:
Antibiotic resistance is a major global healthcare crisis. It is expected that antimicrobial resistance 
will overtake cancer as the leading cause of death by 2050 (de Kraker et al., 2016). Tuberculosis (TB) 
is the most devastating infectious disease caused by Mycobacterium tuberculosis (MTB), claiming 1.4 
million lives in 2015. It has existed for millennia and remains a global health problem (Falzon et al., 
2017). The effective treatment for drug-susceptible TB is a 6-month dose regimen of four first-line 
drugs: isoniazid (INH), rifampicin (RIF), ethambutol (ETH) and pyrazinamide (PYZ). The most 
challenging problem with the current TB regimen is patient compliance attributed to the length, 
complexity and adverse effects commonly observed with frontline treatment. This is further 
complicated by the emergence of drug resistant strains. The emergence of drug-resistant TB is one 
of the most dangerous threats to global TB control (Brouqui et al., 2017). The treatment for RIF 
resistant TB (RR-TB), multidrug-resistant TB (MDR-TB), and extensively drug-resistant TB (XDR-TB) 
takes 18-24 months, requiring more expensive and toxic drugs (Upadhyaya et al., 2012). There is an 
urgent need to develop new drugs that can shorten the treatment regimen, that are able to treat 
MDR-TB and have less adverse effects.  Phenotypic screening is emerging as an important tool in the 
discovery of new drugs against MTB as it allows a direct and measurable response of whole cells 
against a library of compounds measuring and evaluating their efficacy in bacterial killing (Kotz, 
2012). Advances in high throughput screening, genome sequencing and data handling tools have 
further expanded its applications allowing the discovery of new anti-microbial compounds and new 
targets (Ferraris et al., 2018). The success of whole cell phenotypic screening is evidenced by the 
recent development of some new TB drugs such as bedaquiline (Matteelli et al., 2010) and others 
which are currently under study (Singh and Mizrahi, 2017).  Whereas target-based approaches have 
encountered very limited success in the antibacterial field (Abrahams et al., 2012; Payne et al., 
2007). 
INH is a frontline anti-TB drug that inhibits the mycobacterial enoyl-reductase InhA and its activity is 
dependent on KatG activation, the catalase peroxidase involved in the activation of isoniazid.   InhA 
is an essential enzyme for the biosynthesis of a major component of the mycobacterial cell wall, 
mycolic acid, through fatty acid synthesis (FAS-II) system (Duan et al., 2014). InhA is also a target for 
second line drug ethionamide (Banerjee et al., 1994).  Unfortunately, between 40 to 95% of INH-
resistant MTB clinical isolates have mutations in KatG gene leading to decreased activation of INH  
(Hazbon et al., 2006; Seifert et al., 2015) and therefore this pro-drug activation step of INH 
mechanism of action significantly contributes to multidrug and extensively drug resistance in MTB 
isolates (Ramaswamy et al., 2003). It is therefore important to develop drugs that can directly inhibit 
InhA without requiring activation by KatG.
Chalcones are essential intermediate compounds for the synthesis of various heterocyclic 
compounds such as flavonoids and isoflavanoids which are abundant in edible plants (Rachmale and 
Patil, 2012).  Many studies have shown that natural and synthetic chalcones display a wide spectrum 
of biological activities (Chavan et al., 2015) including anti-TB activity (Gomes et al., 2017). 
In view of their therapeutic potential, a series of 15 synthetic chalcones were evaluated in vitro for 
their anti-mycobacterial activity against the MTB model organism M. bovis BCG using whole cell 
phenotypic screening.  In addition, the mode of action of the hit compound was elucidated and 
validated using biochemical, molecular genetics and molecular docking approaches.  
2 Materials and Methods:
2.1 Synthesis: Chalcones (1a-1o) were synthesized by reacting 3,4-dimethoxybenzaldehyde with 
various acetophenones by the Claisen-Schmidt condensation (Figure 1). The synthesized products 
were recrystallized from appropriate solvents and were characterized by spectral analysis, melting 
point, infrared spectroscopy, 1H and 13C NMR and mass spectrometry. 
2.2 Anti-mycobacterial evaluation: Minimum inhibitory concentrations (MICs) were determined for 
these synthesized compounds by broth micro-dilution according to CLSI recommended procedure as 
described previously (Abrahams et al., 2012).  To prepare stocks, M. bovis BCG Pasteur was grown to 
mid-logarithmic phase (Optical density 600 nm = 0.5-0.8) in Middlebrook 7H9 broth (Difco) 
supplemented with 10 % albumin dextrose catalase supplement (ADC); 0.25% (v/v) glycerol and 
0.05 % (v/v) Tween 80. 
MIC of each test compound was determined against M. bovis BCG in a 96-well flat-bottom, 
microtitre plate in a final volume of 200 µl. Series of two-fold dilutions of test compounds starting 
from 200 µg.ml-1 and the standard (RIF) were prepared in Middlebrook 7H9 medium from stock 
solution (10 mg.ml-1 in DMSO). The inoculum was standardized to approximately 1×106 cfu.ml-1 and 
100 µl was added to each well. All plates were sealed using seals (Sigma, UK Z380069) to prevent 
desiccation of the peripheral wells and incubated at 37°C without shaking for six days. A 25 µl 
resazurin solution (0.02% w/v in sterile distilled water) was added to each well and the plates were 
incubated for 24 hours. The MIC was defined as the lowest concentration where there was no colour 
change of resazurin (blue) to resarufin (pink). Experiments were performed with biological replicates 
(n=3). 
2.3 MTT Assay for Cytotoxicity: The in vitro cytotoxicity of all synthesized chalcones (1a-1o) was 
assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay against J774 
cells at a concentration range of 200-0.5 μg.ml-1.
 
Exponentially growing mouse macrophages (J774) 
in Dulbecco’s Modified Eagle’s medium (DMEM) (supplemented with 10 % FBS and 1% penicillin and 
streptomycin) were seeded at a density of 50,000 cells.ml-1 into a 96-well plate and incubated 
overnight at 37C (Ling et al., 2015). The medium was replaced with fresh medium containing 
synthesized chalcones (1a-1o) and after 24 h of incubation at 37C, MTT was added to the cells.  
After 2 h, the formed crystals were dissolved in isopropanol and the absorbance was recorded using 
plate reader at A540nm. The experiments were performed in biological replicates of n=3.
2.4 Scanning Electron Microscopy (SEM): All chemicals and reagents for electron microscopy were 
obtained from Sigma Aldrich, M. bovis BCG (Pasteur strain, ATCC 35734) cultures were grown to 
early log phase (optical density at 600 nm, 0.2), at which time cells were treated with 1a (60 µg.ml-1), 
followed by incubation at 37oC for five days. Cells were harvested by low-speed centrifugation and 
washed in 0.1 M cacodylate (CACO) buffer (pH 7.3). Washed cells were then fixed on glass coverslips 
in 0.1 M CACO buffer (pH 7.3) containing 2.0  % glutaraldehyde–osmium tetroxide (1:1, v/v) for 45 
minutes at 4°C (Parrish et al., 2001). Secondary fixation was done at 4oC overnight in a mixture of 
4.0% formaldehyde and 1.0 % glutaraldehyde. Samples were post-fixed at room temperature for 1 h 
in 0.1 M CACO buffer containing 1% tannic acid and dehydrated through a graded ethanol series of 
50, 70, 95 (twice), and 100% (three times) (Stadtländer, 2008). The samples were air dried and 
coated with gold and visualized using JEOL CarryScope JCM-5700 scanning electron microscope. 
2.5 Extraction and Analysis of MAMES and FAMES: The inhibition of mycolic acid biosynthesis by 1a 
was investigated. The qualitative and quantitative biochemical characterization of the mycolic acid 
pattern by thin layer chromatography (TLC) can be used to address how drugs alter mycolic acid 
biosynthesis (Alahari et al., 2007a, 2007b; Hartkoorn et al., 2012). To assess the effect of 1a on both 
mycolic acid and fatty acid synthesis in M. bovis BCG, mycolic acid methyl esters (MAMES) and fatty 
acid methyl esters (FAMES) were prepared from cultures following labelling with [4]-acetate (Cox et 
al., 2016).  Following the treatment with 1a the total FAMEs and -mycolate and keto-mycolic acid 
methyl esters (- and k-MAMEs) were extracted and analyzed by autoradiography TLC using 
petroleum ether-diethyl ether (95:5) six times as described in Parish and Stoker (Parish and Stoker, 
1998). 
2.6 MIC shift assay: The mycobacterial expression vector pMV261 was cloned with M. tuberculosis 
FAS-II enzymes KasA, KasB, FabH, HadABC, MabA, MabB and InhA. Each respective plasmid was 
electroporated into M. bovis BCG and the MIC assay was performed using these transformed strains, 
along with an empty pMV261 control strain (Larsen et al., 2002).  The data points were collected in 
triplicate and an IC50 (50% inhibition of growth) values for each strain were obtained using GraphPad 
Prism software. The experiments were performed in biological replicates of n=3.
2.7 Intrinsic tryptophan fluorescence ligand binding assay:  Using intrinsic tryptophan fluorescence, 
a ligand binding assay was performed to measure the binding affinity of 1a to InhA enzyme. Briefly, 
InhA (10 µM) was incubated for 5 minutes in a buffer solution (25 mM HEPES, 10% glycerol and 300 
mM NaCl, pH 8) at 25°C followed by addition of increasing concentrations 0.3 to 70 μM of either 
triclosan (positive control) or compound 1a. DMSO concentration was maintained at less than 1% in 
the assay. The measurements were obtained as a change in tryptophan fluorescence by Hitachi 
F7000 spectrophotometer at an excitation wavelength of 350 nm and emission wavelength at 470 
nm. Data were recorded using Hitachi FL Solutions 4.6 software. The experiments were performed in 
biological replicates of n=3.  
2.8 Molecular Docking:
2.8.1 Protein preparation: The X-ray crystal structure of InhA complexed with PT506 inhibitor 
(5UGU) was obtained from protein data bank (www.rcsb.org). Protein preparation wizard module of 
Schrödinger suite was used to prepare the protein by adding hydrogens, fixing error like missing side 
chains, assigning correct bond orders, adjusting the ionization and tautomeric states (via epik). All 
the water molecules have been deleted. Optimisation of the hydrogen bonding network and the 
orientation of the hydroxyl/thiol groups, terminal amide groups in Asn, Gln and His states was 
carried out using the ProtAssign algorithm. Finally, restrained minimization was carried out on all the 
atoms using OPLS3 force fields, with converge heavy atoms to RMSD set to 0.3 Å (default).
2.8.2 Ligand Preparation: Compound 1a was drawn and prepared using Ligprep module, which 
performed addition of hydrogens, 2D to 3D conversion, generation of ionization and tautomeric 
states (via Epik) at physiological pH 7.0 ± 2.0, and also generated ring conformations using default 
settings.  Compound 1a was energy minimized using OPLS3 force fields.
2.8.3 Docking studies:  The X-ray crystal structure of InhA (PDB ID 5UGU, resolution 1.95 Å) was used 
for structure-based docking of compound 1a. The Receptor Grid generation was carried out by 
identifying the PT506 inhibitor in the 5UGU crystal structure and excluding it from the grid 
generation. The triazole based inhibitor PT506 present in 5UGU crystal structure was redocked to 
verify our Glide docking protocol. Glide docking successfully reproduced the crystallographic binding 
mode of triazole based inhibitor with a high docking score of -11.00. The RMSD value between the 
heavy atoms of the Glide predicted pose and the crystallographic binding pose is 0.31 Å, indicating 
close agreement. We have used this docking protocol to dock compound 1a to 5UGU (InhA) using 
Schrödinger GLIDE, in standard precision (SP) mode. Molecular modelling studies were performed 
primarily using Schrödinger drug design software suite (Schrödinger, 2017). 
3 Results: 
The MIC values (μg.ml-1) of chalcones (1a-1o) (Table 1) were obtained with RIF as the standard. The 
results were obtained in duplicate by testing in concentrations ranging 200-0.3 μg.ml-1. Compounds 
that exhibited higher selectivity index (SI) values for J774 cells were considered nontoxic. Hence 
compound 1a (SI=8.4) was selected for mode of action (MoA) elucidation.
Preliminary SEM examination of the 1a-treated cells indicate definite morphological changes 
occurred in comparison to the control due to the action of the drug. The SEM examination revealed 
in general there are some degraded cells in 1a-treated cells. The main features of the cells in control 
specimen (Figure 2a-2c) are smooth surface and characteristic rod like shape. Whereas the cells 
exposed to 1a for five days showed elongation, wrinkles and bulging (Figure 2d-2f). 
3.1 Mode of Action: 
3.1.1 FAMEs and MAMEs Analysis:  To identify the biological target of 1a, inhibition of mycolic acid 
biosynthesis was investigated.  As shown in Figure 3 there was a dose-dependent decrease in the 
production of - and k-MAMEs upon treatment with 1a. There is also an accumulation of FAMEs in a 
dose-dependent manner. This accumulation of FAMEs and reduction of MAMEs suggests that test 
compound 1a inhibits mycolic acid biosynthesis (FAS-II inhibition) in mycobacteria which causes 
cessation of the essential mycolic acids. This inhibition of FAS-II is desirable as the inhibition of FAS-I 
is not specific since mammalian fatty acid synthases are similar to FAS-I. Original auto-radiograph of 
MAMEs and FAMEs is included in supplementary data (Figure S-1).
3.1.2 MIC Shift:  To further corroborate that 1a inhibits mycolic acid biosynthesis, MIC shift assay 
was performed.  M. bovis BCG containing the pMV261::inhA plasmid exhibited an increased IC50 over 
the empty vector control (16 g.ml-1 compared to 8 g.ml-1 respectively). The results suggest that the 
ample growth of InhA over-expressor strain was observed as shown by increase in absorbance 
(Figure 4), indicating an increase in resistance. This further validates InhA as the target of the 
chalcone compound series.  The data for the other overexpressing components of FAS-II are listed in 
supplementary data (Figure S-2).
3.1.3 Intrinsic Tryptophan Fluorescence InhA Binding Assay:  Intrinsic tryptophan fluorescence was 
used to investigate InhA as the target enzyme for 1a. Ligand binding assays using InhA were 
conducted to establish the equilibrium dissociation constant (Kd) values for compounds 1a and 
triclosan. Binding affinity is the strength of the binding interaction between a protein and its ligand, 
that is measured and reported by Kd values. Triclosan is well known for its direct binding affinity 
towards InhA.  The experimental results suggest that both Triclosan and 1a bind with similar affinity 
to InhA, as reflected by the Kd values of 10.29 µM and 11.65 µM respectively providing the necessary 
evidence for target validation (Figure 5). Kd values (mean± s.d) resulting from non-linear least-
squares fitting of a one-site specific binding model are listed in supplementary Table S-1. 
 
3.1.4 Binding mode analysis of compound 1a:  Predicted binding mode of the compound 1a with 
the binding site of InhA (Figure 6a and 6b) suggested that it occupies the hydrophobic cavity of the 
substrate binding site. Substrate binding pocket is composed of hydrophobic groups from the side 
chains of Tyr 158, Phe 149, Met 199, Met 166 and Pro 193. Compound 1a (SP docking score -9.14) is 
involved in good hydrophobic interactions with these amino acids and also involved in van der Waals 
interactions with the surrounding amino acids Pro193, Met 199, Phe 149. In addition, the phenyl ring 
of compound 1a undergoes Pi-Pi stacking interactions with the phenyl ring of Phe 149. It appears 
that hydrophobic, van der Waals, Pi-Pi stacking interactions play a dominant role in the binding 
affinity of the compound 1a.
4 Discussion: 
Treatment of drug resistant strains of M. tuberculosis has become a global problem and WHO has 
declared the priority of new drugs to overcome antibiotic resistance. To overcome this problem 
many approaches including the re-purposing of broad spectrum anti-bacterials, target-based 
programs on antimycobacterial enzymes and phenotypic screening have been widely reported 
(Chetty et al., 2017). The target to drug approach for drug discovery is time consuming and costly.  In 
comparison, a drug to target approach that involves phenotypic screening utilizes whole cells and is 
much quicker and establish potent inhibitors at low cost. In this study we have synthesized 15 
chalcones, fully characterized them and using whole cell phenotypic screening approach showed 
that most of these chalcones showed antimycobacterial activity (Table 1) with MIC in the range 6.25-
200 µg.ml-1 against M. bovis BCG.  Compound 1a was the most potent against M. bovis BCG with MIC 
of 6.25 µg.ml-1 and showed SI of 8.0. Of the fifteen compounds synthesized 1a, where R substituents 
are all hydrogens, showed the best activity. The compounds that had substituents other than 
hydrogen did not display the same level of activity. This may reflect poor binding of the substituents 
in the other fourteen compounds. The compounds which also showed significant activity were those 
which contained a chlorine or a bromine atom. Previously reported work on in vitro testing on 
antifungal and antimycobacterial activity of a series of pyrazine analogues of chalcones showed the 
highest potency was exhibited by derivatives with a chlorine or a bromine atom in positions 2 and 4 
of the benzoyl ring (Kucerova-Chlupacova et al., 2016).  The ortho chloro-substituent (R1=Cl), 
compound 1f, showed the next best activity compared to compound 1a. When the chlorine atom is 
positioned in the para position (R3=Cl), compound 1g, there is quite a substantial drop in activity, but 
when the R3 position is occupied by a bromine atom, compound 1d, the activity is comparable to 
compound 1f.  This may indicate that electronic factors do not play an important role in activity.  
Calculated lipophilicities of all tested compounds are provided in table 1. They do not correlate with 
the biological activity of the compounds.  The activity of compounds 1a-1o does not show a 
correlation with electronic factors nor lipophilicities; it is therefore surmised that the conformation 
of particular molecules, influenced by the position of the halogen atom, may play an important role.  
Our results are in accordance with previous studies where it has been shown that chalcone 
derivatives show activity against gram-negative, gram-positive bacteria and mycobacteria (Gond et 
al., 2013; Lin et al., 2002; Sivakumar et al., 2007; Yadav et al., 2014). A series of 5- nitro-substituted 
heteroaryl chalcones were synthesised using QSAR driven approach (Gomes et al., 2017). They have 
shown low MICs against non-replicating M. tuberculosis H37Rv and RIF and INH mono-resistant 
strains. As the functional groups attached to the 3 carbon α,β unsaturated carbonyl structure are 
different from our chalcone series the results cannot be directly compared to each other. However, 
having a 5- nitro-heteroaryl group instead of an aromatic carbon ring B of our chalcone series seems 
advantageous resulting lower MICs values. 
In the present study using in vitro biochemical and modelling experiments, we have shown that our 
hit compound 1a specifically targets mycolic acid synthesis component InhA.  The mycolic acids are 
the essential characteristic components of mycobacterial cell wall and involves two distinct fatty acid 
synthesis pathways- FAS-I and FAS-II. The FAS-II system enables fatty acid elongation forming 
meromycolic acids  in the presence  of condensing  enzymes KasA  and  KasB (Kremer et al., 2002), a 
keto  reductase MabA (Marrakchi et al., 2002), a dehydratse HadABC (Sacco et al., 2007), and an 
enoyl acyl carrier protein reductase InhA (Banerjee et al., 1994). The lipid analysis in our study 
showed dose dependent accumulation of FAMEs with depletion of MAMEs confirming that 
compound 1a specifically inhibits FAS-II in mycolic acid biosynthesis (Figure 3).  Furthermore, the 
mycobacterial strains transformed with overexpression plasmids (pMV261) containing InhA 
conferred an increase in resistance to compound 1a and no resistance was observed with empty 
vector pMV261 (Figure 4). This further validates that mycolic acid synthesis is inhibited by compound 
1a and InhA is the possible target.  InhA is one of the best validated targets in the treatment of TB.  
The pro drug INH is oxidatively activated by the catalase-peroxidase KatG and covalently binds to 
NAD to form an adduct that inhibits the activity of InhA (Rawat et al., 2003). It is anticipated that a 
drug directly targeting InhA in a different location than activated INH and not requiring activation by 
KatG may have bactericidal and sterilizing properties superior to those of INH.  
To ascertain whether compound 1a directly targets InhA without requiring KatG activation, we 
conducted ligand binding tryptophan flourescence assay. Triclosan inhibits InhA directly, without 
requiring the activation of KatG (Gurvitz, 2010). It was observed that compound 1a shows similar 
binding affinity to triclosan (Figure 5), thus suggesting that compound 1a directly inhibits InhA.  
Computational studies also provided further evidence of the binding affinity of compound 1a 
towards the target site InhA as shown in Figure 6 (a and b).  Compound 1a showed hydrophobic 
interactions with Tyr 158, Phe 149, Met 199, Met 166 and Pro 193 and is also involved in π-π 
interactions with Phe 149 residues of InhA.  It is also involved in van der Waals interactions with 
surrounding amino acids.  Similar to our work Yadav  and co-workers by their docking studies have 
shown that the chalcone derivatives bind to InhA with good affinity as compared with the standard 
inhibitors such as triclosan and isoniazid (Yadav et al., 2014). They also showed hydrophobic 
interactions with Tyr and Phe residues but in addition to these residues they also showed the 
interaction with other amino acid residues of the InhA, including aliphatic (Gly-93 and Ile-200), sulfur 
containing (Met-159 and Met-206), cyclic (Pro-191), and basic (Lys-163) residues. Recently Joshi et al 
(2017) have used target to drug approach and shown that compounds such as pyrrolyl 
benzohydrazide derivatives inhibit InhA directly. Similarly Stular et al (Stular et al., 2016)  using 
molecular docking found three novel compounds that bind InhA. Biological testing confirmed that 
these compounds inhibit InhA. Muradas et al (Muradás et al., 2018) have studied the inhibitory 
activity of quinoxaline derived chalcones against M. tuberculosis and showed MIC values in the range 
of 3.13 µg.ml-1 to 12.5 µg.ml-1 which are very similar to our results.  However, in contrast to our 
results they showed that these chalcones did not inhibit mycolic acid synthesis as they showed low 
MICs against M. tuberculosis strains that have mutations in the katG or inhA genes. The results 
cannot be directly compared due to the difference in the functional groups.
5 Conclusion:
 Following the identification and validation of the molecular target, target-specific optimization of 
compound 1a will be pursued to improve efficacy and reduce toxicity. This will be achieved using 
computational and synthetic chemistry techniques to rationally design novel inhibitors based on our 
understanding of ligand-protein (1a-InhA) interaction. 
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